Top

Published in:

01-08-2014 | Preclinical study

Association study of susceptibility loci with specific breast cancer subtypes in Chinese women

Authors: Bo Zhang, Yang Li, Longnian Li, Mengyun Chen, Cuicui Zhang, Xian-bo Zuo, Fu-sheng Zhou, Bo Liang, Jun Zhu, Pan Li, Zhong-lian Huang, Han Xuan, Wei Li, Zhen-dong Chen

Published in: Breast Cancer Research and Treatment | Issue 3/2014

Abstract

To determine whether recent genome-wide association studies that reported 45 susceptibility loci in European women are also risk factors for breast cancer in Chinese women. We selected and genotyped 40 single nucleotide polymorphisms (SNPs) using the Sequenom iPlex platform in a female Chinese cohort of 2,901 breast cancer cases and 2,789 healthy controls. We evaluated these SNPs with the risk of breast cancer and further by estrogen receptor (ER) status, progestin (PR) status, human epidermal growth factor receptor-2 (HER-2) status, and four breast cancer subtypes (Luminal A type, Luminal B type, HER-2 overexpression type and Basal-like type). We first confirmed that the SNP rs9693444 on 8p12 was associated with breast cancer in Chinese women (P = 6.44 × 10⁻⁴). Furthermore, we identified four susceptibility loci that were associated with specific tumor subtypes. Statistically significant differences were detected with the association of rs6828523 (4q34.1/ADAM29) with ER-positive breast cancer (P = 1.27 × 10⁻³) and the association of rs4849887 (2q14.2) with PR-positive breast cancer (P = 1.29 × 10⁻³). Of the four breast cancer subtypes, the associations of rs12493607 (3p24.1/TGFBR2) with HER-2 overexpression in breast cancer (P = 1.09 × 10⁻³) and rs11075995 (16q12.2/FTO) with basal-like breast cancer (P = 1.64 × 10⁻⁴) were statistically significant. This study is the first to show that these 5 susceptibility loci (8p12, 4q34.1/ADAM29, 2q14.2, 3p24.1/TGFBR2, and 16q12.2/FTO) correlate with breast cancer (overall and specific subtypes) in Chinese women, which has improved our understanding of the genetic basis of specific breast cancer subtypes.

Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2(3):133–140PubMedCrossRef

Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087–1093PubMedCentralPubMedCrossRef

Zhang B, Li Y, Zheng X, Zuo X, Zhou F, Liang B, Zhu J, Li P, Ding Y, Huang Z (2013) A common variant in the SIAH2 locus is associated with estrogen receptor-positive breast cancer in the chinese han population. PLoS One 8(11):e79365PubMedCentralPubMedCrossRef

D B, MR V, C H, Y L, B Z, E S, WD D, XJ Z, F W (2013) Comparison of genetic variation of breast cancer susceptibility genes in Chinese and German populations. Eur J Hum Genet 13(10):38

Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45(4):353–361PubMedCentralPubMedCrossRef

Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS (2013) Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45(4):392–398PubMedCentralPubMedCrossRef

Goldhirsch A, Wood W, Coates A, Gelber R, Thürlimann B, Senn H-J (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747PubMedCentralPubMedCrossRef

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, De Bakker PI, Daly MJ (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559–575PubMedCentralPubMedCrossRef

Keyse SM (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27(2):253–261PubMedCrossRef

10.

Gröschl B, Bettstetter M, Giedl C, Woenckhaus M, Edmonston T, Hofstädter F, Dietmaier W (2013) Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation. Int J Cancer 132(7):1537–1546PubMedCrossRef

11.

Teutschbein J, Haydn JM, Samans B, Krause M, Eilers M, Schartl M, Meierjohann S (2010) Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins. BMC Cancer 10(1):386PubMedCentralPubMedCrossRef

12.

Sieben NL, Oosting J, Flanagan AM, Prat J, Roemen GM, Kolkman-Uljee SM, van Eijk R, Cornelisse CJ, Fleuren GJ, van Engeland M (2005) Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 23(29):7257–7264PubMedCrossRef

13.

H-y Wang, Cheng Z, Malbon CC (2003) Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 191(2):229–237CrossRef

14.

Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci 98(5):621–628PubMedCrossRef

15.

Shiomi T, Okada Y (2003) MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 22(2–3):145–152PubMedCrossRef

16.

Fq Wang, So J, Reierstad S, Fishman DA (2005) Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 114(1):19–31CrossRef

17.

Wei X, Moncada-Pazos A, Cal S, Soria-Valles C, Gartner J, Rudloff U, Lin JC, Rosenberg SA, López-Otín C, Samuels Y (2011) Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. Hum Mutat 32(6):E2148–E2175PubMedCentralPubMedCrossRef

18.

Eriksson N, Benton GM, Do CB, Kiefer AK, Mountain JL, Hinds DA, Francke U, Tung JY (2012) Genetic variants associated with breast size also influence breast cancer risk. BMC Med Genet 13(1):53PubMedCentralPubMedCrossRef

19.

Ikram MS, Neill GW, Regl G, Eichberger T, Frischauf A-M, Aberger F, Quinn A, Philpott M (2004) GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Investig Dermatol 122(6):1503–1509PubMedCrossRef

20.

Kubo M, Nakamura M, Tasaki A, Yamanaka N, Nakashima H, Nomura M, Kuroki S, Katano M (2004) Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64(17):6071–6074PubMedCrossRef

21.

Jin G, Wang L, Chen W, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Shen J (2007) Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer 120(6):1330–1335PubMedCrossRef

22.

Biswas S, Trobridge P, Romero-Gallo J, Billheimer D, Myeroff LL, Willson JK, Markowitz SD, Grady WM (2008) Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor β resistant cells. Genes Chromosom Cancer 47(2):95–106PubMedCrossRef

23.

Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257–2261PubMedCentralPubMedCrossRef

24.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750PubMedCentralPubMedCrossRef

25.

Kaklamani V, Yi N, Sadim M, Siziopikou K, Zhang K, Xu Y, Tofilon S, Agarwal S, Pasche B, Mantzoros C (2011) The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Med Genet 12(1):52PubMedCentralPubMedCrossRef

26.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef

27.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750PubMedCentralPubMedCrossRef

28.

Cornen S, Guille A, Adélaïde J, Addou-Klouche L, Finetti P, Saade M-R, Manai M, Carbuccia N, Bekhouche I, Letessier A (2014) Candidate luminal B breast cancer genes identified by genome, gene expression and dna methylation profiling. PLoS One 9(1):e81843PubMedCentralPubMedCrossRef

29.

Network CGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70CrossRef

30.

Norum J, Andersen K, Sørlie T (2014) Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. Br J Surg 100:589–598

31.

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thürlimann B, Senn H-J, Albain KS, André F, Bergh J (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223PubMedCentralPubMedCrossRef

Title: Association study of susceptibility loci with specific breast cancer subtypes in Chinese women
Authors: Bo Zhang
Yang Li
Longnian Li
Mengyun Chen
Cuicui Zhang
Xian-bo Zuo
Fu-sheng Zhou
Bo Liang
Jun Zhu
Pan Li
Zhong-lian Huang
Han Xuan
Wei Li
Zhen-dong Chen
Publication date: 01-08-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-3041-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression

Long-term cognitive function change among breast cancer survivors

Adolescent physical activity and inactivity: a prospective study of risk of benign breast disease in young women

Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial

RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase

Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States

Keynote webinar | Spotlight on antibody–drug conjugates in cancer